|
|
|
|
UC Reverses Policy on Direct Investments in Startups
The University of California (UC) system has reversed policy that stopped UC campuses from investing directly in their own technology startups. The ban was originally established as part of UC's 1998 Guidelines on University-Industry Relations Policy. |
|
|
|
ArmaGen Enters Licensing/Collaboration Deal with Shire
UCLA Startup, ArmaGen, recently announced that it has licensed to Shire the worldwide commercialization rights to its investigational Hunter syndrome drug AGT-182, one of its two lead programs. The deal could net ArmaGen up to $225 million.
|
|
|
|
Save the Date: UCLA Advanced Materials Partnering Conference | Nov. 5, 2014, 9AM-4PM, UCLA
The conference includes panelists from corporate and venture capital firms, as well as domestic and international regulatory bodies. Startups and inventors from academic institutions across the SoCal region will be in attendance. |
|
|
Kythera Announces FDA Acceptance of ATX-101 NDA
KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). If approved, ATX-101 will be the first non-surgical treatment for the reduction of submental fat. |
|
|
|
Venturing into a New Model - UCLA VC Fund
The UCLA venture capital fund’s distinctive membership structure has shaped its culture to be more of an incubator or club rather than a mostly financial sponsor like the Stanford and Utah funds. |
|
|
Intellectual Property Announcements
New U.S. Patents Awarded
-
8,793,618 - Launching of multiple dashboard sets that each correspond to different. . . | N. Martin, et al.
-
8,791,092 - Molecular tweezers for the treatment of amyloid-related diseases | S. Frautschy, et al.
-
8,785,602 - EMP2 antibodies and methods of use thereof for causing regression of a. . . | A. Wu, et al.
-
8,779,104 - EMP2 antibodies and methods of use thereof causing regression of a. . . | J. Braun, et al.
-
8,778,608 - CA9 gene single nucleotide polymorphisms predict prognosis and. . . | A. Belldegrun, et al.
-
8,775,984 - Phase coherent differential structures | F. Chang, et al.
-
8,773,964 - CDMA-based crosstalk cancellation for on-chip global high-speed links | S. Pamarti, et al.
-
8,772,853 - All graphene flash memory device | K. Wang, et al.
-
8,772,041 - Membrane precursors and membranes formed therefrom | J. Schmidt, et al.
-
8,766,341 - Epitaxial growth of single crystalline MgO on germanium | R. Kawakami, et al.
-
8,765,459 - Apparatus and methods for manipulation and optimization of biological. . . | R. Sun, et al.
-
8,765,147 - Endophytic fungi from Pteromischum sp. plant, compounds and. . . | D. Teplow, et al.
~~~~
New UCLA Technologies Available for Licensing
SEARCH MORE TECHNOLOGIES
~~~~
|
|
|
|
UCLA Invents - Previous Issue / Archive |
- Fibrocell Science Announces Exclusive License with UCLA
- UCLA Startup, Kite Pharma, Raises $128M in IPO
- CytoVale Raises $4.3M Series A for Early Sepsis Detection
- Inventors and Startup CEOs Share Advice at OIP-ISR Event
- New UCLA Technologies Available for Licensing
- Jobs @ UCLA Startups
- Read Previous Issue | View Newsletter Archive
|
|
|
|
|
UCLA Invents Newsletter, Vol. 2, No. 12
How to Subscribe:
http://oip.ucla.edu/UCLAinvents
View Newsletter Archive
Send editorial comments and corrections to:
Bob Nidever, Editor, bnidever@research.ucla.edu
Contributors: Neil Bajpayee, Howard Chang, Miles Gerson
UCLA Invents is published by the UCLA Office of Intellectual Property & Industry Sponsored Research
11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 | http://oip.ucla.edu
Copyright © 2014 The Regents of the University of California. All Rights Reserved.
|
|
|
|